Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Am Coll Cardiol ; 74(6): 744-754, 2019 Aug 13.
Artigo em Inglês | MEDLINE | ID: mdl-31395124

RESUMO

BACKGROUND: The prevalence of pulmonary embolism (PE) in patients presenting with syncope to the emergency department (ED) is largely unknown. This information, however, is necessary to balance the potential medical benefit or harm of systematic PE screening in patients presenting with syncope to the ED. OBJECTIVES: This study sought to determine the prevalence of PE in patients with syncope. METHODS: Unselected patients presenting with syncope to the ED were prospectively enrolled in a diagnostic multicenter study. Pre-test clinical probability for PE was assessed using the 2-level Wells score and the results of D-dimer testing using age-adapted cutoffs. Presence of PE was evaluated by imaging modalities, when ordered as part of the clinical assessment by the treating ED physician or by long-term follow-up data. RESULTS: Long-term follow-up was complete in 1,380 patients (99%) at 360 days and 1,156 patients (83%) at 720 days. Among 1,397 patients presenting with syncope to the ED, PE was detected at presentation in 19 patients (1.4%; 95% confidence interval [CI]: 0.87% to 2.11%). The incidence of new PEs or cardiovascular death during 2-year follow-up was 0.9% (95% CI: 0.5% to 1.5%). In the subgroup of patients hospitalized (47%), PE was detected at presentation in 15 patients (2.3%; 95% CI: 1.4% to 3.7%). The incidence of new PEs or cardiovascular death during 2-year follow-up was 0.9% (95% CI: 0.4% to 2.0%). CONCLUSIONS: PE seems to be a rather uncommon cause of syncope among patients presenting to the ED. Therefore, systematic PE-screening in all patients with syncope does not seem warranted. (BAsel Syncope EvaLuation Study [BASEL IX]; NCT01548352).

2.
J Am Coll Cardiol ; 74(4): 483-494, 2019 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-31345421

RESUMO

BACKGROUND: The European Society of Cardiology (ESC) recommends the 0/1-h algorithm for rapid triage of patients with suspected non-ST-segment elevation myocardial infarction (MI). However, its impact on patient management and safety when routinely applied is unknown. OBJECTIVES: This study sought to determine these important real-world outcome data. METHODS: In a prospective international study enrolling patients presenting with acute chest discomfort to the emergency department (ED), the authors assessed the real-world performance of the ESC 0/1-h algorithm using high-sensitivity cardiac troponin T embedded in routine clinical care and its associated 30-day rates of major adverse cardiac events (MACE) (the composite of cardiovascular death and MI). RESULTS: Among 2,296 patients, non-ST-segment elevation MI prevalence was 9.8%. In median, 1-h blood samples were collected 65 min after the 0-h blood draw. Overall, 94% of patients were managed without protocol violations, and 98% of patients triaged toward rule-out did not require additional cardiac investigations including high-sensitivity cardiac troponin T measurements at later time points or coronary computed tomography angiography in the ED. Median ED stay was 2 h and 30 min. The ESC 0/1-h algorithm triaged 62% of patients toward rule-out, and 71% of all patients underwent outpatient management. Proportion of patients with 30-day MACE were 0.2% (95% confidence interval: 03% to 0.5%) in the rule-out group and 0.1% (95% confidence interval: 0% to 0.2%) in outpatients. Very low MACE rates were confirmed in multiple subgroups, including early presenters. CONCLUSIONS: These real-world data document the excellent applicability, short time to ED discharge, and low rate of 30-day MACE associated with the routine clinical use of the ESC 0/1-h algorithm for the management of patients presenting with acute chest discomfort to the ED.

3.
Am J Med ; 132(12): 1431-1440.e7, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31306621

RESUMO

BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients with a history of acute coronary syndrome. This is a 2-year study of atrial fibrillation patients with or without a history of acute coronary syndromes. METHODS: Adults with newly diagnosed atrial fibrillation and ≥1 investigator-defined stroke risk factor were enrolled in GARFIELD-AF between March 2010 and September 2015. The association between prior acute coronary syndromes and long-term outcomes was determined using a Cox proportional hazards model, adjusting for baseline risk factors, oral anticoagulation (OAC) ± antiplatelet (AP) therapy, and usual care. RESULTS: Of 39,679 patients, 10.5% had a history of acute coronary syndromes. At 2-year follow-up, patients with prior acute coronary syndromes had higher adjusted risks of stroke/systemic embolism (hazard ratio [HR] 1.39; 95% confidence interval [CI], 1.08-1.78), major bleeding (HR 1.30; 95% CI, 0.95 -1.79), all-cause mortality (HR 1.34; 95% CI, 1.21 -1.49), cardiovascular mortality (HR 1.85; 95% CI, 1.51-2.26), and new acute coronary syndromes (HR 3.42; 95% CI, 2.62-4.45). Comparing antithrombotic therapy in the acute coronary syndromes vs no acute coronary syndromes groups, most patients received OAC ± AP: 60.8% vs 66.1%, but AP therapy was more likely in the acute coronary syndromes group (68.1% vs 32.9%), either alone (34.9% vs 20.8%) or with OAC (33.2% vs 12.1%). Overall, 17.8% in the acute coronary syndromes group received dual AP therapy with (5.3%) or without OAC (12.5%). Among patients with moderate/high risk for stroke/systemic embolism, fewer in the acute coronary syndromes group received OAC with or without AP therapy (Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, prior Stroke, TIA, or thromboembolism, Vascular disease, Age 65-74 years, Sex category [CHA2DS2-VASc] 2: 52.1% vs 64.6%; CHA2DS2-VASc ≥3: 62.0% vs 70.7%), and the majority with a Hypertension (uncontrolled systolic blood pressure >160 mm Hg), Abnormal renal or liver function, previous Stroke, Bleeding history or predisposition, Labile international normalized ratios, Elderly, and concomitant Drugs or alcohol excess (HAS-BLED) score ≥3 were on AP therapy (83.8% vs 65.5%). CONCLUSIONS: In GARFIELD-AF, previous acute coronary syndromes are associated with worse 2-year outcomes and a greater likelihood of under-treatment with OAC, while two-thirds of patients receive AP therapy. Major bleeding was more common with previous acute coronary syndromes, even after adjusting for all risk factors.

4.
Rev. urug. cardiol ; 33(3): 231-251, dic. 2018. tab
Artigo em Espanhol | LILACS-Express | ID: biblio-979068

RESUMO

Resumen: La miocardiopatía dilatada (MCD) es la forma más común de disfunción ventricular con una prevalencia en adultos de alrededor de 1/2.500 individuos. Durante muchos años la forma más descripta de MCD en los registros fue la idiopática. En los últimos diez años, los avances en las imágenes y la genética han permitido identificar formas específicas dentro de este grupo que llamábamos comúnmente idiopático. El estudio de los pacientes con MCD debe seguir los pasos habituales, comenzando con el trabajo clínico, evaluación de antecedentes personales y familiares, examen físico, y análisis profundo de electrocardiograma y ecocardiograma. La identificación de las características clínicas sugestivas de enfermedades específicas debería conducir a un trabajo de diagnóstico de segundo nivel que puede incluir análisis bioquímicos específicos, resonancia cardíaca, estudios anatomopatológicos y genéticos. A continuación repasamos estrategias para la mejor identificación de etiologías específicas.


Summary: Dilated cardiomyopathy is the most common form of ventricular dysfunction with an adult prevalence of about 1 / 2.500 individuals. For many years the most described form of dilated cardiomyopathy in the registries was the idiopathic form. In the last ten years, advances in imaging and genetics have made it possible to identify specific forms within this group that we commonly called idiopathic. The study of patients with dilated cardiomyopathy should follow the usually steps, beginning with clinical work, evaluation of personal and family history, physical examination, and deep electrocardiogram analysis and echocardiography. The identification of clinical features suggestive of specific diseases should lead to a second-level diagnostic work that may include specific biochemical analyzes, cardiac resonance, anatomopathological and genetic studies. Next, we review strategies for the best identification of specific etiologies.

5.
Rev. argent. cardiol ; 86(5): 15-24, oct. 2018.
Artigo em Espanhol | LILACS-Express | ID: biblio-1003219

RESUMO

RESUMEN Introducción: El score HEART consiste en una prueba sencilla que fue diseñada para estratificar a los pacientes que consultan al servicio de emergencias por dolor torácico, según su riesgo de presentar un síndrome coronario agudo a corto plazo. Fue creado inicialmente con troponina de cuarta generación, pero el advenimiento de la troponina de alta sensibilidad impuso su incorporación al score y la reevaluación de su comportamiento. Objetivo: Nos propusimos evaluar el comportamiento del score HEART con troponina de alta sensibilidad. Material y métodos: Se realizó un estudio prospectivo que incluyó 1464 pacientes (p) que consultaron al servicio de emergencia por dolor torácico y que tenían electrocardiograma sin elevación del segmento ST. Se evaluó la incidencia de MACE (combinado de infarto agudo de miocardio, muerte y revascularización) a 30 días. Resultados: El índice clasificó 739 pacientes (50,5 %) como de bajo riesgo, 515 pacientes (35,2%) de riesgo intermedio y 210 pacientes (14,3%) de alto riesgo. La incidencia de la combinación de infarto agudo de miocardio, muerte y revascularización fue del 1,35% en el primer grupo; del 20%, en el segundo; y del 71%, en el tercero (long rank test p < 0,001). El área bajo la curva global para la combinación de infarto agudo de miocardio, muerte y revascularización fue de 0,91 (0,89-0,93). Conclusiones: El score HEART que utiliza troponina de alta sensibilidad tiene una gran capacidad para clasificar pacientes con dolor torácico de acuerdo con su riesgo de presentar eventos cardiovasculares en el corto plazo.

6.
Rev. argent. cardiol ; 86(5): 68-70, oct. 2018.
Artigo em Espanhol | LILACS-Express | ID: biblio-1003225

RESUMO

RESUMEN Introducción: La disección coronaria espontánea (DCE) es una causa infrecuente de síndrome coronario agudo (SCA). Es conocida su mayor frecuencia en mujeres jóvenes; sin embargo, sus características clínicas y evolutivas permanecen insuficientemente estudiadas. Objetivo: Evaluar las características clínicas y la evolución de la DCE y su comparación con el síndrome coronario agudo ateroesclerótico (SCAA) en mujeres jóvenes. Material y métodos: Estudio de cohorte prospectivo, realizado entre 2015 y 2017, en el que se compararon mujeres menores de 60 años que ingresaron por SCA por DCE con otro cohorte que presentaba SCAA. Resultados: Se incluyeron 49 pacientes, 7 (14,29%) presentaban DCE. La mediana de seguimiento fue de 10 meses (Pc 25-75 2-18). La mediana de edad fue de 44 años (Pc 25-75 38-45) en grupo DCE y de 55 (Pc 25-75 49-58) en SCAA (P = 0,002), con mayor prevalencia de hipertensión arterial, dislipemia en grupo SCAA (69% vs. 14,3% P = 0,006 y 71% vs. 14% P = 0,004 respectivamente). En el grupo DCE hubo mayor estrés (57,1% vs. 4,8% P = 0,001) y uso de ergotamina (28,6% vs. 0% P = 0,0001) y se presentaron más frecuentemente como infarto agudo de miocardio con elevación del ST (71,4% vs. 28,6%; P = 0,02. El punto final primario ocurrió en 3 pacientes (42,9%) del grupo con DCE y fue menor en el SCAA (9,5%, P = 0,02. En el seguimiento, el 14,9% del grupo DCE y el 14,8% de SCAA presentaron el punto final secundario (P = 0,9). Conclusiones: Las mujeres con DCE tuvieron menor prevalencia de factores de riesgo cardiovascular y presentaron un SCA con peor impacto hemodinámico y mayores complicaciones. La evolución a largo plazo no mostró diferencias significativas.


ABSTRACT Background: Spontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndrome (ACS). Its prevalence is higher in young women, but its clinical characteristics and outcome remain insufficiently studied. Objective: The aim of this study was to evaluate the baseline characteristics and outcome of SCAD compared with atheroscle-rotic acute coronary syndrome (AACS) in young women. Methods: This prospective cohort study compared women <60 years admitted with ACS due to SCAD with another cohort with AACS, between 2015 and 2017. Results: A total of 49 patients were included, 7 of which (14.29%) presented SCAD. Median follow-up was 10 months (25-75 IQR: 2-18). Median age was 44 years (25-75 IQR: 38-45) in the SCAD group and 55 years (25-75 IQR: 40-58) in the AACS group (p=0.002), with greater prevalence of hypertension and dyslipidemia (69% vs. 14.3%, p=0.006 and 71% vs. 14% p=0.004, respectively). Episodes of acute stress (57.1% vs. 4.8%, p=0.001) and use of ergotamine (28.6% vs. 0%, p=0.0001) were more common in the SCAD group, and ST-segment elevation myocardial infarction was the most frequent presentation (71.4% vs. 28.6%; p=0.02). The primary endpoint occurred in 3 patients (42.9%) of the SCAD group and was less frequent in the AACS group (9.5%, p=0.02). During follow-up, 14.9% of patients in the SCAD group and 14.8% in the AACS group presented the secondary endpoint (p=0.9). Conclusions: Women with SCAD had lower prevalence of cardiovascular risk factors and presented ACS with worse hemody-namic impact and more complications. The long-term outcome did not show significant differences.

7.
Medicina (B Aires) ; 78(2): 71-75, 2018.
Artigo em Espanhol | MEDLINE | ID: mdl-29659354

RESUMO

Apocal hypertrophic cardiomyopathy (AHCM) is a phenotypic variant within hypertrophic cardiomyopathies, in which ventricular repolarization alterations are present. These electrocardiographic disturbances can mimic an anterior infarction which triggers a series of studies and treatments that may be unnecessary. The aim of this study was to describe and compare electrocardiographic differences in a series of patients with AHCM and apical non-ST segment elevation myocardial infarction in patients (NSTEMI) with T-wave changes. We conducted an observational and retrospective study, including patients with diagnosed AHCM (N = 19) and apical NSTEMI (N = 19) with negative T waves in V1 and V6 lead of the EKG. Those with AHCM presented higher T-wave voltage (7 mV vs. 5 mV, p = 0.001) and peak voltage (29 mV vs. 17 mV, p = 0.003), higher R-waves (25 mV vs. 10 mV, p = 0.0001), and a maximum voltage of R and T sum (R + T) significantly higher (33 vs. 14, p = 0.00001). They also showed a greater T-wave asymmetry, with a TiTp / TpTf ratio > 1. At a cut-off value of 26.5 mV for the R + T variable, 68% sensitivity and 100% specificity were obtained to diagnose AHCM. This study shows the existence of major differences in electrocardiographic presentation of AHCM and apical NSTEMI.


Assuntos
Cardiomiopatia Hipertrófica/fisiopatologia , Eletrocardiografia , Infarto do Miocárdio/fisiopatologia , Adulto , Idoso , Cardiomiopatia Hipertrófica/diagnóstico , Estudos Transversais , Diagnóstico Diferencial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Sensibilidade e Especificidade
8.
Medicina (B.Aires) ; 78(2): 71-75, abr. 2018. graf, tab
Artigo em Espanhol | LILACS-Express | ID: biblio-954952

RESUMO

La miocardiopatía hipertrófica apical (MCHA) es una variante fenotípica dentro de las miocardiopatías hipertróficas que presenta alteraciones de la repolarización ventricular. Estos cambios electrocardiográficos pueden simular en muchos casos un infarto anterior, lo que dispara una serie de estudios y tratamientos que pueden ser innecesarios. El objetivo del trabajo fue describir y comparar las diferencias electrocardiográficas en una serie de pacientes con MCHA e infarto sin elevación del ST apicales (IAMSESTa) que presenten cambios tipo T en el electrocardiograma (ECG). Se realizó un estudio observacional y retrospectivo, incluyendo pacientes con diagnóstico de MCHA (n = 19) e IAMSESTa (n = 19) con ondas T negativas en ECG de ingreso en derivaciones V1-V6. Se excluyeron aquellos con MCHA y enfermedad coronaria asociada. Se analizaron las características clínicas y electrocardiográficas entre ambos grupos. Los pacientes con MCHA presentaron mayor voltaje de ondas T (7 mV vs. 5 mV; p = 0.001) y sumatoria de voltaje de las mismas (29 mV vs. 17 mV; p = 0.003), mayor voltaje de ondas R (25 mV vs. 10 mV; p = 0.0001), con una sumatoria de máximo voltaje de R y T (R+T) significativamente mayor (33 vs. 14; p = 0.00001). Presentaron además mayor asimetría de las ondas T negativas, objetivado mediante una relación TiTp/TpTf > 1. Con un valor de corte de 26.5 mV para la variable R+T, se obtuvo un 68% de sensibilidad y 100% de especificidad para diagnosticar MCHA. El presente trabajo demuestra la existencia de diferencias en el patrón del ECG en MCHA e IAMSESTa.


Apocal hypertrophic cardiomyopathy (AHCM) is a phenotypic variant within hypertrophic cardiomyopathies, in which ventricular repolarization alterations are present. These electrocardiographic disturbances can mimic an anterior infarction which triggers a series of studies and treatments that may be unnecessary. The aim of this study was to describe and compare electrocardiographic differences in a series of patients with AHCM and apical non-ST segment elevation myocardial infarction in patients (NSTEMI) with T-wave changes. We conducted an observational and retrospective study, including patients with diagnosed AHCM (N = 19) and apical NSTEMI (N = 19) with negative T waves in V1 and V6 lead of the EKG. Those with AHCM presented higher T-wave voltage (7 mV vs. 5 mV, p = 0.001) and peak voltage (29 mV vs. 17 mV, p = 0.003), higher R-waves (25 mV vs. 10 mV, p = 0.0001), and a maximum voltage of R and T sum (R + T) significantly higher (33 vs. 14, p = 0.00001). They also showed a greater T-wave asymmetry, with a TiTp / TpTf ratio > 1. At a cut-off value of 26.5 mV for the R + T variable, 68% sensitivity and 100% specificity were obtained to diagnose AHCM. This study shows the existence of major differences in electrocardiographic presentation of AHCM and apical NSTEMI.

9.
Rev. argent. cardiol ; 86(2): 126-130, abr. 2018.
Artigo em Espanhol | LILACS-Express | ID: biblio-1003189

RESUMO

RESUMEN: Introducción: El síndrome de burnout genera impacto negativo en la actuación profesional, la seguridad del paciente y la vida del residente. Esta problemática ha tomado vigencia en las residencias argentinas; sin embargo, no se han evaluado medidas efectivas para prevenir su aparición. Objetivo: Evaluar la prevalencia del síndrome de burnout antes y después de la implementación del descanso postguardia en médicos residentes de cardiología. Material y métodos: Estudio analítico, prospectivo. Se implementó el cuestionario de Maslach en residentes de cardiología de una institución de la Ciudad de Buenos Aires, antes y después de la implementación de un período de descanso de 24 horas (DPG) luego de una guardia de 24h. Resultados: La encuesta fue respondida por 42 residentes (2014: 19; 2015: 23). Hubo una tendencia a menor prevalencia de burnout en el grupo con DPG (26,1% vs. 47,4% p = 0,152) y mejores resultados en la escala de despersonalización (19 11-21 vs. 10 [1-17] p = 0,023). Presentaron menor agotamiento y despersonalización las mujeres y los mudados a Buenos Aires. Conclusiones: La implementación del DPG se asoció a la reducción de la escala de despersonalización, principalmente en mujeres. Se remarca la importancia de crear estrategias de prevención que mejoren las condiciones de trabajo y la calidad de vida del residente.

10.
Echocardiography ; 35(7): 935-940, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29505666

RESUMO

INTRODUCTION: Atrial fibrillation (AF) occurs in about 20%-25% of patients with hypertrophic cardiomyopathy and is associated with increased risk of cardioembolism and heart failure impacting on patients' morbidity and mortality. The aim of this study was to identify echocardiographic predictors of AF in a cohort of patients with hypertrophic cardiomyopathy (HCM). METHODS: Patients were recruited from 2 centers: Buenos Aires Cardiovascular Institute and the Hospital Vall d'Hebron of Barcelona which were analyzed together. Retrospective study using electronic charts. RESULTS: A total of 321 patients with HCM and no documented history of AF were included. Median follow-up was 3 years. Mean age was 54 ± 16 years. Obstructive HCM was present in 41% of the patients, and 94.2% had preserved systolic function. Thirty-eight patients developed AF during the follow-up period (11.8%). Univariate analysis showed that age, maximum myocardial thickness, atrial area, an E/e' ratio ≥ 17, and systolic pulmonary pressure estimated by echocardiography were associated with new-onset AF. Multivariate analysis showed that E/e' ≥ 17 ratio {HR 3.27 ([1.10-9.27] P = .033)} and atrial area {HR 1.06 ([1.01-1.13] P = .037)} remained predictors of AF. CONCLUSIONS: An E/e' ratio ≥ 17, as an expression of left ventricular filling pressures with impact on the left atrium, and left atrial area ≥28 cm2 are strong predictors of AF in patients with HCM.


Assuntos
Fibrilação Atrial/diagnóstico , Função do Átrio Esquerdo/fisiologia , Cardiomiopatia Hipertrófica/complicações , Ecocardiografia/métodos , Átrios do Coração/diagnóstico por imagem , Função Ventricular Esquerda/fisiologia , Fibrilação Atrial/epidemiologia , Fibrilação Atrial/etiologia , Cardiomiopatia Hipertrófica/diagnóstico , Cardiomiopatia Hipertrófica/fisiopatologia , Feminino , Átrios do Coração/fisiopatologia , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Morbidade/tendências , Estudos Retrospectivos , Espanha/epidemiologia , Taxa de Sobrevida/tendências
11.
Am J Emerg Med ; 36(6): 911-915, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29111332

RESUMO

INTRODUCTION: Floating right heart thrombi (FRHTS) are a rare phenomenon associated with high mortality. Immediate treatment is mandatory, but optimal therapy is controversial. OBJECTIVE: To compare the clinical characteristics according to different treatment strategies and to identify predictors of mortality on patients with FRHTS. METHODS: We conducted a systematic search of reported clinical cases of TTRH from 2006 to 2016. RESULTS: 207 patients were analyzed, median age was 60years, 51.7% were men, 31.4% presented with shock. Pulmonary thromboembolism was present in 85% of the cases. The treatments administered were anticoagulation therapy in 44 patients (21.28%), surgical embolectomy in 89 patients (43%), thrombolytic therapy in 66 patients (31.8%), percutaneous thrombectomy in 3 patients (1.93%) and fibrinolytic in situ in 4 (1.45%). The overall mortality rate was 21.3%. The mortality associated with anticoagulation alone was higher than surgical embolectomy or thrombolysis (36.4 vs 18% vs 18.2%, respectively, p=0.03), and in percutaneous thrombectomy and fibrinolytics in situ was 0%. At multivariate analysis, only anticoagulation alone (odds ratio [OR] 2.4, IC 95% 1.07-5.4, p=0.03), and shock (OR 2.87 (IC 95% 1.3-5.9, p=0.005) showed a statistically significant effect on mortality. CONCLUSION: FRHTS represent a serious form of thromboembolism that requires rapid decisions to improve the survival. Anticoagulation as the only strategy does not seem to be sufficient, while thrombolysis and surgical thrombectomy show better and similar results. A proper individualization of the risk and benefits of both techniques is necessary to choose the most appropriate strategy for our patients.


Assuntos
Anticoagulantes/uso terapêutico , Previsões , Trombectomia/métodos , Terapia Trombolítica/métodos , Trombose , Ecocardiografia , Eletrocardiografia , Saúde Global , Átrios do Coração , Cardiopatias/diagnóstico , Cardiopatias/epidemiologia , Cardiopatias/terapia , Ventrículos do Coração , Humanos , Morbidade/tendências , Publicações Periódicas como Assunto , Taxa de Sobrevida/tendências , Trombose/diagnóstico , Trombose/epidemiologia , Trombose/terapia
12.
J Atr Fibrillation ; 9(6): 1530, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29250287

RESUMO

Cardiac troponin assays have provided a significant contribution for the early diagnosis of cardiovascular events. There is significant evidence about the association between the absolute value of elevated cardiac troponin levels with the prognosis of patients with chest pain. However, it is well-known that elevated cardiac troponin levels may occur in situations other than acute coronary syndromes, as it happens with atrial fibrillation. The significance and prognosis of this elevation are not entirely clear. We review the evidence about the meaning of such elevation in the setting of atrial fibrillation.

13.
Rev. chil. cardiol ; 36(3): 244-248, dic. 2017. ilus
Artigo em Espanhol | LILACS | ID: biblio-899592

RESUMO

Resumen: Se presenta el caso de un paciente de sexo femenino de 42 años sin antecedentes clínicos de relevancia, con hipopotasemia severa y cambios electrocardiográficos imitando isquemia miocárdica con enfermedad corona-ria de múltiples vasos.


Abstracts: A 42-year-old woman with no previous medical history developed severe hypokalemia. The ECG changes suggested multivessel coronary artery disease with ischemia in several territories.


Assuntos
Humanos , Feminino , Adulto , Isquemia Miocárdica/diagnóstico , Eletrocardiografia , Hipopotassemia/diagnóstico , Potássio/uso terapêutico , Isquemia Miocárdica/etiologia , Diagnóstico Diferencial , Hipopotassemia/complicações , Hipopotassemia/tratamento farmacológico
14.
Am J Emerg Med ; 34(8): 1579-82, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27306263

RESUMO

INTRODUCTION: Right ventricular (RV) dysfunction has proved to be an important predictor of morbidity and mortality in patients with pulmonary embolism (PE). Tricuspid annular plane systolic excursion (TAPSE) is one of the parameters that have been validated as predictor of outcomes. The aim of our study was to evaluate the performance (sensitivity and specificity) of high-sensitivity cardiac troponin T (hs-cTnT) to predict RV dysfunction defined as TAPSE <16 mm. METHODS: We conducted a single-center retrospective analysis of 40 patients prospectively included. Median age was 66 years (59-76) and PESI score was 81 (67-100). RESULTS: Right ventricular dysfunction was present in 30% of the patients and was associated with higher median troponin values (33.5 ng/L vs 16 ng/L; P= .03). A logarithmic relation was observed between hs-cTnT and lower TAPSE values (r(2)= 0.36; P< .0001). The area under the ROC curve of hs-cTnT to predict RV dysfunction was 0.77 (0.63-0.92). CONCLUSION: hs-cTnT is a biomarker with good performance to identify RV dysfunction in PE.


Assuntos
Embolia Pulmonar/sangue , Troponina/sangue , Função Ventricular Direita/fisiologia , Doença Aguda , Idoso , Biomarcadores/sangue , Ecocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/fisiopatologia , Curva ROC , Reprodutibilidade dos Testes , Estudos Retrospectivos
15.
Pacing Clin Electrophysiol ; 39(6): 588-91, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27000950

RESUMO

BACKGROUND: High-sensitivity cardiac troponin assays have provided a significant contribution for the early diagnosis of cardiovascular events. However, elevated cardiac troponin levels may occur in other clinical situations as supraventricular tachyarrhythmias with concerns about the mechanism of this elevation. OBJECTIVES AND METHODS: The goal of this study was to describe the performance of high-sensitivity cardiac troponin T (hs-cTnT) assay in patients presenting to the emergency department with a primary diagnosis of supraventricular tachyarrhythmia and to evaluate its relation with cardiovascular events during follow-up. RESULTS: One hundred patients were included; mean age was 64 ± 12 years and 59.8% were men. The most common arrhythmia at admission was atrial fibrillation (68%), followed by atrial flutter (16%) and reentrant tachycardia (16%). The results of the first determination of hs-cTnT were positive (>14 ng/L) in 44.2% of the patients and the second determination was positive in 50.7% of the cases. The variation between the first and the second troponin levels was 1 (0-5) ng/L, and was >7 ng/L in 24.6% of the cases, with a clear trend toward higher troponin values in reentrant tachycardias. Four events were reported at 30 days; in all the cases the patients had presented atrial fibrillation and there were no significant differences in hs-cTnT values. CONCLUSIONS: There are a significant number of patients with supraventricular tachyarrhythmias who present elevated hs-cTnT levels. The association of this elevation with cardiovascular events seems to be very low.


Assuntos
Taquicardia Supraventricular/sangue , Troponina/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sensibilidade e Especificidade
16.
Cardiol J ; 21(3): 304-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-23990184

RESUMO

BACKGROUND: Vernakalant is a new, safe and effective drug used intravenously, which has proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone, and flecainide in clinical studies. Until now no study has been conducted comparing the perception of state of health in patients who received vernakalant versus propafenone or flecainide for conversion of recent-onset AF. The aim of our study is to compare the change of perception of state of health from screening to hour 2 in patients treated with vernakalant and propafenone or flecainide for conversion of recent-onset AF. METHODS: Eighty hemodynamically stable patients with recent onset AF without structural heart disease were prospectively included. A single oral dose of propafenone 600 mg was administered to 30 patients, 30 patients received intravenous vernakalant and the remaining 20 patients received a single oral dose of flecainide 300 mg. Clinical, laboratory variables and perception of state of health from screening to hour 2 treated with these drugs measured by the EQ-5 D quality-of-life assessments visual analog scale were recorded. RESULTS: Baseline characteristics were similar in the three groups. Treatment with vernakalant resulted in a significantly greater improvement in patient perception of state of health at hour 2 compared with propafenone and flecainide. In the vernakalant group, a mean increase (from baseline) of 12.1 points was seen compared with a mean increase of 5.4 points in the propafenone group or 5.2 points in flecainide group (p < 0.01). CONCLUSIONS: The change of perception of state of health from screening to hour 2 treated with vernakalant had a significantly statistical improvement compared with propafenone or flecainide for conversion recent-onset AF.


Assuntos
Anisóis/administração & dosagem , Fibrilação Atrial/tratamento farmacológico , Nível de Saúde , Percepção , Pirrolidinas/administração & dosagem , Qualidade de Vida , Administração Oral , Idoso , Fibrilação Atrial/psicologia , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Flecainida/administração & dosagem , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Propafenona/administração & dosagem , Estudos Prospectivos , Resultado do Tratamento , Bloqueadores do Canal de Sódio Disparado por Voltagem/administração & dosagem
17.
Am J Emerg Med ; 31(8): 1226-9, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23810070

RESUMO

BACKGROUND: Chest pain represents between 5% and 10% of annual visits to emergency departments (EDs) and near 25% of hospitalizations. Characterization of chest pain is sometimes difficult, and strategies should focus on preventing inappropriate discharge of patients with acute coronary syndrome. The goal of our study is to compare negative predictive value of the algorithm in the chest pain unit using the fourth-generation troponin T assay (4GTT) vs high-sensitivity troponin T assay (HSTT). METHODS: We included 600 patients with probable acute coronary syndrome, who were discharged from the chest pain unit without an acute coronary syndrome: 300 patients in the 4GTT group and 300 patients in the HSTT group. Clinical and laboratory variables were analyzed. All the patients were followed up at 30 days, and the cardiovascular events were recorded. RESULTS: Major cardiac events occurred in only 3 (1.2%) in the HSTT group vs 5 (1.7%) in the 4GTT group (P, nonsignificant). The negative predictive value was 99% in both groups. Emergency department length of stay was 4.3 ± 2.6 hours in HSTT group vs 10 ± 3.4 hours in the 4GTT group (P = .01). CONCLUSION: The algorithm in the chest pain unit using HSTT showed to have the same negative predictive value as the algorithm with the 4GTT but with a shorter stay in the ED.


Assuntos
Síndrome Coronariana Aguda/diagnóstico , Troponina T/sangue , Síndrome Coronariana Aguda/sangue , Síndrome Coronariana Aguda/complicações , Idoso , Algoritmos , Angina Instável/sangue , Angina Instável/diagnóstico , Dor no Peito/diagnóstico , Dor no Peito/etiologia , Técnicas de Apoio para a Decisão , Serviço Hospitalar de Emergência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/sangue , Infarto do Miocárdio/diagnóstico , Valor Preditivo dos Testes , Sensibilidade e Especificidade , Fatores de Tempo
19.
Cardiovasc Ther ; 31(6): 377-80, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23683253

RESUMO

INTRODUCTION: An oral loading dose of propafenone 600 mg is used in our center as in other places around the world for conversion of recent-onset atrial fibrillation (AF) in patients without structural heart disease. Vernakalant is a novel, safe, and effective drug used intravenously and has proved to be more rapid in converting recent-onset AF to sinus rhythm compared with placebo and amiodarone. There is no study that compares vernakalant with propafenone. The aim of our study is to compare the time taken for conversion of recent-onset AF in patients treated with vernakalant and propafenone. METHODS: Thirty-six hemodynamically stable patients with recent-onset AF without structural heart disease were prospectively included. A single oral dose of propafenone 600 mg was administered to 19 patients and 17 received intravenous vernakalant. Clinical and laboratory variables, conversion rate, and time to conversion were recorded. RESULTS: Baseline characteristics were similar in both groups. Time to conversion to sinus rhythm was of 166 min (120-300) in the propafenone group versus 9 min (6-18) in the vernakalant group (P = 0.0001). Conversion rate was of 78% in the propafenone group at 8 h and of 93% in the vernakalant group at 2 h; yet, this difference was not statistically significant (P = 0.4). Time to conversion had a direct impact in hospital stay, which was 43% shorter in the vernakalant group (P = 0.0001). CONCLUSION: Time to conversion of AF to sinus rhythm was significantly shorter in the vernakalant group compared with the propafenone group and was associated with shorter hospital stay.


Assuntos
Anisóis/uso terapêutico , Antiarrítmicos/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Propafenona/uso terapêutico , Pirrolidinas/uso terapêutico , Idoso , Anisóis/efeitos adversos , Feminino , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Propafenona/efeitos adversos , Estudos Prospectivos , Pirrolidinas/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA